There are 2949 resources available
1673MO - The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
Presenter: Astrid LIÈVRE
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
812MO - Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Presenter: Nicoletta Colombo
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1421MO - Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
815MO - The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Presenter: Benoit You
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
816MO - AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)
Presenter: Fabrice Lecuru
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1424MO - Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA35 - Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer
Presenter: Panagiotis Konstantinopoulos
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA36 - Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Presenter: Ana Oaknin
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
614MO - Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
Presenter: Mihaela Aldea
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA22 - Imaging based PCa screening among BRCA mutation carriers: Results from the first round of screening
Presenter: David Margel
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast